Company: OSRH
Filing Date: 2025-01-31
Form Type: 424B3
Source: 0001213900-25-008874
Chunk: 452

Company: OSR Holdings, Inc.
Filing Date: 2025-01-31
Form: 424B3
Chunk 452
---
.Bang, and Ms. Nam there were no bonuses or any other form of non -equityincentive compensation paid or accrued. Defined Contribution Plan OSR Holdings currently maintains a defined contribution plan for all of its officers and employees as required by Korean law. A defined contribution plan is a retirement pension plan in which OSR Holdings pays a fixed amount of contributions to a separate fund for the benefit of each employee, which is one twelfth (1/12) of annual salary to the retirement plan. Director Compensation Since inception, all of the board directors of OSR Holdings have been also serving as executive officers of the company and received the cash compensation disclosed above, except for Mr. Hwang, who receives no cash compensation for his service as an executive officer or director. OSR Holdings does not pay directors any cash or equity -basedcompensation for their service as directors. 286 OSR HOLDINGS MANAGEMENT’S DISCUSSION AND ANALYSIS OF FIN ANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion should be read in conjunction with “Unaudited Pro Forma Condensed Consolidated Combined Financial Information,” “Selected Historical Financial Data of OSR Holdings” and OSR Holdings’ audited and unaudited condensed consolidated financial statements, including the notes thereto, included elsewhere in this proxy statement / prospectus. In addition to historical financial information, this discussion contains forward -looking statements based upon OSR Holdings’ current expectations that involve risks and uncertainties. OSR Holdings’ actual results could differ materially from such forward -looking statements as a result of various factors, including those set forth under “Risk Factors” and elsewhere in this proxy statement / prospectus. Historical information contained in this section refers to OSR Holdings and its consolidated subsidiaries (where applicable) prior to the completion of the Business Combination; forward looking information contained in this section refers to New OSR Holdings following BLAC’s acquisition of OSR Holdings (as described below and in other sections of this proxy statement / prospectus). References included in this section to “we”, “its,” “us” and “our” refer to OSR Holdings and its consolidated subsidiaries. Introduction OSR Holdings is a global drug development company, dedicated to advancing healthcare outcomes and improving the quality of life for people and their families. We aim to build and develop a robust portfolio of innovative and potentially transformative therapies. Although we are indication agnostic, our initial focus is addressing unmet needs in oncology and immunology. As a data -drivencompany, we leverage our existing and expanding network